Evidence map›Paper›PMID 37792008›Full record

ArticleWorld journal of urology2023

Nephrometry scores to predict oncological outcomes following partial nephrectomy (UroCCR Study 70).

Martin Lorette, Jean-Christophe Bernhard, Charles-Karim Bensalah, Pierre Bigot, Arnauld Villers, Marie Lou Letouche, Nicolas Doumerc, Philippe Paparel, François Audenet, François-Xavier Nouhaud and 15 more

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 19 institutions in 2 countries.

Martin LoretteDepartment of Urology, Lille University Hospital, Lille, France. martin6lorette@gmail.com.
Jean-Christophe BernhardDepartment of Urology, University Hospital, Bordeaux, France.
Charles-Karim BensalahDepartment of Urology, Rennes University Hospital, Rennes, France.
Pierre BigotDepartment of Urology, University Hospital, Angers, France.
Arnauld VillersDepartment of Urology, Lille University Hospital, Lille, France.
Marie Lou LetoucheDepartment of Urology, University Hospital, Tours, France.
Nicolas DoumercDepartment of Urology, University Hospital of Rangueil, Toulouse, France.
Philippe PaparelDepartment of Urology, University Hospital, Lyon Sud, France.
François AudenetDepartment of Urology, Georges Pompidou European University Hospital, Paris, France.
François-Xavier NouhaudDepartment of Urology, University Hospital, Rouen, France.
Bastien ParierDepartment of Urology, Kremlin Bicetre University Hospital, Paris, France.
Thibault TricardDepartment of Urology, University Hospital, Strasbourg, France.
Cécile ChampyDepartment of Urology, Mondor University Hospital, Créteil, France.
Martin BrenierDepartment of Urology, St Joseph Hospital, Paris, France.
Géraldine PignotDepartment of Urology, Paoli-Calmettes Institute, Marseille, France.
Jean-Alexandre LongDepartment of Urology, University Hospital, Grenoble, France.
Matthieu DurandDepartment of Urology, University Hospital, Nice, France.
Maxime ValleeDepartment of Urology, University Hospital, Poitiers, France.
Thibaut WaeckelDepartment of Urology, University Hospital, Caen, France.
Romain BoissierDepartment of Urology, University Hospital, Marseille, France.
Ricky TambweDepartment of Urology, University Hospital, Reims, France.
Idir OuzaidDepartment of Urology, Bichat University Hospital, Paris, France.
Jonathan Olivier *Department of Urology, Lille University Hospital, Lille, France.
Zine-Eddine Khene *Department of Urology, Rennes University Hospital, Rennes, France.
members of the French Committee of Urologic Oncology (CCAFU)
Centre Hospitalier Universitaire de Rennes · FRAssistance Publique Hôpitaux de Marseille · FRBicêtre Hospital · FRCentre Hospitalier Universitaire de Nice · FRCentre Hospitalier Universitaire de Reims · FRHôpital Européen Georges-Pompidou · FRHôpital Lyon Sud · FRHôpital Rangueil · FRInstitut Mondor de Recherche Biomédicale · FRInstitut Paoli-Calmettes · FRKyushu University Hospital · JPUniversité d'Angers · FRUniversité de Bordeaux · FRUniversité de Caen Normandie · FRUniversité de Poitiers · FRUniversité de Rouen Normandie · FRUniversité de Strasbourg · FRUniversité de Tours · FRUniversité Grenoble Alpes · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePartial nephrectomy (PN) for large or complex renal tumors can be difficult and associated with a higher risk of recurrence than radical nephrectomy. We aim to evaluate the clinical useful of nephrometry scores for predicting oncological outcomes in a large cohort of patients who underwent PN for renal cell carcinomas.

methodsOur analysis included patients who underwent PN for renal cell carcinoma in 21 French academic centers (2010-2020). RENAL, PADUA, and SPARE scores were calculated based on preoperative imaging. Uni- and multivariate cox models were performed to identify predictors of recurrence-free survival and overall survival. The area under the curve (AUC) was used to identify models with the highest discrimination. Decision curve analyses (DCAs) determined the net benefit associated with their use.

resultsA total of 1927 patients were analyzed with a median follow-up of 32 months (14-45). RENAL score (p = 0.01), age (p = 0.002), histological type (p = 0.001), high nuclear grade (p = 0.001), necrotic component (p < 0.001), and positive margins (p = 0.005) were significantly related to recurrence in multivariate analyses. The discriminative performance of the 3 radiological scores was modest (65, 63, and 63%, respectively). All 3 scores showed good calibration, which, however, deteriorated with time. Decision curve analysis of the three models for the prediction of overall and recurrence-free survival was similar for all three scores and of limited clinical relevance.

conclusionThe association between nephrometry scores and oncological outcomes after NP is very weak. The use of these scores for predicting oncological outcomes in routine practice is therefore of limited clinical value.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsDiagnostic ImagingHumansKidneyNephrectomyRetrospective StudiesTreatment OutcomeNephrometry scorePartial nephrectomyPredictingRecurrence

Identifiers

PMID37792008
OpenAlexW4387326125

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.